Johnson & Johnson Management

Management criteria checks 2/4

Johnson & Johnson's CEO is Joaquin Duato, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is $28.40M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth €50.15M. The average tenure of the management team and the board of directors is 5 years and 5 years respectively.

Key information

Joaquin Duato

Chief executive officer

US$28.4m

Total compensation

CEO salary percentage5.6%
CEO tenure2.9yrs
CEO ownership0.02%
Management average tenure5yrs
Board average tenure5yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Joaquin Duato's remuneration changed compared to Johnson & Johnson's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 29 2024n/an/a

US$15b

Jun 30 2024n/an/a

US$16b

Mar 31 2024n/an/a

US$17b

Dec 31 2023US$28mUS$2m

US$13b

Oct 01 2023n/an/a

US$12b

Jul 02 2023n/an/a

US$12b

Apr 02 2023n/an/a

US$11b

Jan 01 2023US$13mUS$1m

US$16b

Oct 02 2022n/an/a

US$18b

Jul 03 2022n/an/a

US$17b

Apr 03 2022n/an/a

US$20b

Jan 02 2022US$14mUS$1m

US$18b

Oct 03 2021n/an/a

US$18b

Jul 04 2021n/an/a

US$18b

Apr 04 2021n/an/a

US$15b

Jan 03 2021n/an/a

US$15b

Sep 27 2020n/an/a

US$17b

Jun 28 2020n/an/a

US$15b

Mar 29 2020n/an/a

US$17b

Dec 29 2019US$13mUS$970k

US$15b

Sep 29 2019n/an/a

US$14b

Jun 30 2019n/an/a

US$16b

Mar 31 2019n/an/a

US$15b

Dec 30 2018US$9mUS$934k

US$15b

Sep 30 2018n/an/a

US$2b

Jul 01 2018n/an/a

US$1b

Apr 01 2018n/an/a

US$1b

Dec 31 2017US$19mUS$897k

US$1b

Compensation vs Market: Joaquin's total compensation ($USD28.40M) is above average for companies of similar size in the Austrian market ($USD4.37M).

Compensation vs Earnings: Joaquin's compensation has increased by more than 20% in the past year.


CEO

Joaquin Duato (61 yo)

2.9yrs

Tenure

US$28,397,240

Compensation

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...


Leadership Team

NamePositionTenureCompensationOwnership
Joaquin Duato
CEO & Chairman2.9yrsUS$28.40m0.015%
€ 50.3m
Joseph Wolk
Executive VP & CFO6.4yrsUS$13.91m0.0029%
€ 9.8m
Jennifer Taubert
Executive VP & Worldwide Chairman of Innovative Medicine12.9yrsUS$11.00m0.0064%
€ 21.4m
John Reed
Executive Vice President of Innovative Medicine1.7yrsUS$20.65m0.00061%
€ 2.0m
Robert Decker
Controller & Chief Accounting Officer5yrsno data0.00082%
€ 2.7m
James Swanson
Executive VP & Chief Information Officer5.1yrsno data0.00061%
€ 2.0m
Jessica Moore
Vice President of Investor Relations3.1yrsno datano data
Dirk Brinckman
Chief Compliance Officerno datano datano data
Elizabeth Forminard
Executive VP & Chief Legal Officer2.2yrsno data0.00035%
€ 1.2m
Guy Lebeau
Group Chairman of MD&D Business - EMEAno datano datano data
Kathryn Wengel
Executive VP and Chief Technical Operations & Risk Officer6.4yrsno data0.0034%
€ 11.4m
Vanessa Broadhurst
Executive Vice President of Global Corporate Affairs6.9yrsno data0.00082%
€ 2.7m

5.0yrs

Average Tenure

58yo

Average Age

Experienced Management: JNJ's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joaquin Duato
CEO & Chairman2.9yrsUS$28.40m0.015%
€ 50.3m
Anne Mulcahy
Independent Director15.9yrsUS$410.00k0.00034%
€ 1.1m
Hubert Joly
Independent Director5yrsUS$320.00k0.00021%
€ 698.5k
Marillyn Hewson
Lead Independent Director5.7yrsUS$360.00k0.00012%
€ 399.1k
Paula Johnson
Independent Director1.8yrsUS$352.97k0.000010%
€ 33.3k
Mark McClellan
Independent Director11.2yrsUS$320.00k0%
€ 0
Mary Beckerle
Independent Director9.5yrsUS$355.00k0%
€ 0
Darius Adamczyk
Independent Director2.8yrsUS$340.00k0.000040%
€ 133.0k
Jennifer Doudna
Independent Director6.7yrsUS$320.00k0%
€ 0
Eugene Woods
Independent Director1.1yrsUS$89.15kno data
Mark Weinberger
Independent Director5yrsUS$340.00k0.000040%
€ 133.0k
Nadja West
Independent Director4yrsUS$340.00k0%
€ 0

5.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: JNJ's board of directors are considered experienced (5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 20:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Johnson & Johnson is covered by 62 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays